Clinical trials: Metformin
Healthy
Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets
The primary objective of this trial is to establish bioequivalence of two fixed dose combination (FDC) tablets (containing medium dose empagliflozin/500 mg metformin [Test 1] and low dose empagliflozin/500 mg metformin [Test 2])…
- Trial name
- NCT01844531
- Testing
- empagliflozin, metformin (Glucophage®), empagliflozin and metformin
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin
The purpose of this study is to determine whether PF-06291874 is effective in the treatment T2DM
- Trial name
- NCT02554877
- Testing
- PF-06291874
- Where
- 38 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Pfizer
Type 2 Diabetes, Hyperlipidemia
Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
A 16 week open-label study with subjects receiving background metformin monotherapy. 150 subjects randomized 1:1:1 to receive 1 of the following: open-label colesevelam HCl, open label rosiglitazone, or open-label sitagliptin.
- Trial name
- NCT00484419
- Testing
- Colesevelam HCl, rosiglitazone maleate, sitagliptin phosphate
- Where
- 20 sites in United States
- Volunteers
- 169 people
- Sponsor
- Daiichi Sankyo
Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer
Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
The purpose of this study is to find the benefits of combining nivolumab with metformin in advanced non-small cell lung cancer with and without prior treatment with immunotherapy.
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT03048500
- Testing
- Laboratory Biomarker Analysis, Metformin Hydrochloride, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Northwestern University
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum…
- Trial name
- NCT01778049
- Testing
- BI 10773, BI 10773 / BI 1356
- Where
- 114 sites in United States, Argentina and 9 more
- Volunteers
- 708 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes.
- Trial name
- AWARD-1 (NCT01064687)
- Testing
- LY2189265, Exenatide, Metformin
- Where
- 89 sites in United States, Argentina and 2 more
- Volunteers
- 978 people
- Sponsor
- Eli Lilly and Company
Relapsed Chronic Lymphocytic Leukemia
A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL
Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication. More recently metformin has been shown to act against carcinomas by two mechanisms: 1) an indirect, insulin-dependent mechanism…
- Trial name
- NCT01750567
- Testing
- Metformin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Michigan Rogel Cancer Center
Diabetes Mellitus, Type 2
Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
This study is being done to compare the effectiveness and safety of two treatment paradigms (oral sitagliptin with or without glimepiride versus liraglutide with or without increased dosing) for the treatment of participants with…
- Trial name
- NCT01296412
- Testing
- sitagliptin, liraglutide, glimepiride
- Volunteers
- 653 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes
A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
This clincial trial is evaluating if the co-administration of saxagliptin and dapagliflozin, in addition to metformin, results in better glycemic control, as measured by HbA1c, over a treatment period of 52 weeks, compared to the…
- Trial name
- NCT02419612
- Testing
- Saxagliptin, Dapagliflozin, Glimepiride
- Where
- 84 sites in United States, Czechia and 8 more
- Volunteers
- 444 people
- Sponsor
- AstraZeneca
Age-Related Macular Degeneration, Macular Degeneration, Age-Related
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients…
- Conditions
- Age-Related Macular Degeneration, Macular Degeneration, Age-Related, Dry Macular Degeneration, Geographic Atrophy
- Trial name
- METforMIN (NCT02684578)
- Testing
- Metformin
- Where
- 12 sites in United States
- Volunteers
- 66 people
- Sponsor
- University of California, San Francisco
Diabetes Mellitus, Type II
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086515
- Testing
- Sitagliptin (MK0431), Metformin, Pioglitazone
- Volunteers
- 701 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM
The purpose of this study is to evaluate the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects with Type 2 diabetes mellitus (T2DM) following oral administration of Saxagliptin and…
- Trial name
- NCT01525225
- Testing
- Metformin immediate release (IR), Saxagliptin, Metformin IR
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Diabetes
The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
The aim of this clinical trial is to assess and compare the effect of insulin detemir in combination with liraglutide and metformin versus insulin detemir in combination with insulin aspart and metformin in subjects with very…
- Trial name
- SIMPLE (NCT01966978)
- Testing
- Metformin, Detemir, Liraglutide
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- University of Texas Southwestern Medical Center
Aging, Insulin Sensitivity
Antecedent Metabolic Health and Metformin Aging Study
Aging is the number one risk factor for the majority of chronic diseases. There are no pharmaceutical treatments to slow aging and prolong healthspan.
- Conditions
- Aging, Insulin Sensitivity, Chronic Disease, Mitochondria
- Trial name
- ANTHEM (NCT04264897)
- Testing
- Metformin
- Where
- 2 sites in United States
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Oklahoma Medical Research Foundation
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to insulin lispro (U100) three times a day in participants with type 2 diabetes that are already on insulin glargine (U100), with or…
- Trial name
- SURPASS-6 (NCT04537923)
- Testing
- Tirzepatide, Insulin Lispro (U100)
- Where
- 135 sites in United States, Argentina and 14 more
- Volunteers
- 1,428 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin
This trial is conducted in Asia, Europe, Oceania and South America. The aim of this clinical trial is to generate data demonstrating how to intensify diabetes treatment using BIAsp 30 (biphasic insulin aspart 30) by adding or…
- Trial name
- SIT2MIX (NCT01519674)
- Testing
- biphasic insulin aspart 30, sitagliptin, metformin
- Where
- 69 sites in Argentina, Australia and 8 more
- Volunteers
- 582 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)
MK-8835-016 (B1521006) is designed to evaluate the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729) in participants with Type 2 diabetes mellitus.
- Trial name
- NCT01059825
- Testing
- Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg
- Volunteers
- 375 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes
EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes
Diabetes is increasingly common among youth, forecasting early complications. Type 1 (T1D) cause early heart disease, shortening lifespan despite modern improvements in control of blood sugars and other risk factors for heart…
- Trial name
- EMERALD (NCT01808690)
- Testing
- Metformin
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes Treated With Insulin
Study to Evaluate the Safety and Efficacy of Oral Insulin Formulation in Type 2 Diabetes Mellitus Subjects
The aim of the study was to compare the pharmacodynamic properties of different doses of regular human insulin administered in capsule form twice daily in a randomised twelve-week open-label trial.
- Trial name
- NCT06473662
- Testing
- Oral insulin
- Where
- United Kingdom
- Volunteers
- 153 people
- Sponsor
- Roger New
Diabetes Mellitus, Type 2
Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes
to demonstrate the efficacy of inhaled Technosphere/Insulin in combination with metformin versus combination metformin and a secretagogue
- Trial name
- NCT00332488
- Testing
- Technosphere Insulin, Metformin & Secretagogues, Technosphere Insulin & Metformin
- Where
- 120 sites in United States, Argentina and 9 more
- Volunteers
- 547 people
- Sponsor
- Mannkind Corporation